Clinical Trials

Sponsor: Merck

Sponsor Study ID: MK3475-A18 / ENGOT-CX11

Study Title: A Randomized, Phase 3, Double Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High risk, Locally Advanced Cervical Cancer (KEYNOTE A18 / ENGOT cx11)

NCT Number: NCT04221945

Phase: III

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Cervix Uteri

Study Objectives: The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer.

For more information about the trial above please contact the study team:

Study Documents
(MUSC NetID required for document access)